Time to invest in cardiac surge
Study published by Nature and performed on more than 180.000 patients compared long-term results of heart surgery (bypass grafting, CABG) and percutaneous stenting (PCI). In majority of the patients CABG and PCI are both technically feasible.
Stenting (PCI) since several years has been promoted by business sector including investing in clinical trials supporting this method. Stenting may be more profitable since several procedures can be done in one patient in following weeks. Surgical procedure is one with long lasting durability (once in a lifetime in 90% of patients). Though these efforts PCI never proved better life expectancy than CABG. Moreover, here we’ve got another global study showing that CABG provides lower mortality than PCI.
Not many people know that the risk of PCI and CABG (death in perioperative period) is the same in both these procedures.
So what is the next step for CABG? Next step is to make CABG even safer than PCI. After this step whole balance may change and CABG may dominate the market. Thus, Quantum Innovations has created Heart Sense and Heart Guard technologies. They cover whole market of CABG – on-pump and off-pump techniques. According to analysis performed by our team each of these technologies may reduce the early mortality od CABG by 1 percentage point. This will make CABG safer than PCI – both in short and long-term.